{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22","upperLimit":"50.4","value":"29.2"},{"comment":"Upper confidence limit is not estimable by Kaplan Meier method due to insufficient observed events","groupId":"OG001","lowerLimit":"20.8","upperLimit":"NA","value":"44.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"description":"Measured from time of first study treatment until date of death or date last known alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Carfilzomib : cycle 1 - 20 mg/m\\^2 IV D1, 2 ; 45 mg/m\\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 45 mg/m\\^2 IV D 1, 2, 8, 9, 15, 16\n\nPanobinostat : cycle 1 and cycle 2 to progression - 30 mg D 1, 3, 5, 15, 17, 19","id":"OG000","title":"Dose Level 4 - Escalation and Expansion"},{"description":"Carfilzomib : cycle 1 - 20 mg/m\\^2 IV D1, 2 ; 56 mg/m\\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 56 mg/m\\^2 IV D 1, 2, 8, 9, 15, 16\n\nPanobinostat : cycle 1 and cycle 2 to progression - 20 mg D 1, 3, 5, 15, 17, 19","id":"OG001","title":"Dose Level 6 - Escalation and Expansion"}],"paramType":"MEDIAN","populationDescription":"All patients receiving dose level 4 and dose level 6 doses (both escalation and expansion phases combined) who had a post-baseline disease assessment per protocol were included in the analysis. 3 patients in dose level 4 and 1 patient in dose level 6 did not have a post-baseline assessment and were excluded from analysis.","reportingStatus":"POSTED","timeFrame":"up to 6 years","title":"Overall-survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}